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Key messages
 ► Children with the obese-asthma phenotype may 
exhibit higher degrees of airflow obstruction and 
non-eosinophilic inflammation, which may respond 
more favourably to leukotriene receptor antagonists 
(LTRAs), than inhaled corticosteroids (ICS), due to 
their different modes of action; however, this has not 
yet been studied in children.
 ► Children with excess weight were more likely to 
have an early management failure event (step-up in 
therapy or exacerbation) and respond to LTRA, but 
not low-dose ICS, when compared with their nor-
mal-weight counterparts.
 ► These data support LTRA as a possible alternative 
therapy for mild asthma in children with excess 
weight who may have not previously responded to 
low-dose ICS; further prospective research is war-
ranted to confirm findings.
AbstrAct
Introduction Overweight children with asthma may 
display impaired response to inhaled corticosteroids 
(ICS), possibly due to non-eosinophilic inflammation or 
weight-related lung compression; these mechanisms 
may differentially affect response to ICS and leukotriene 
receptor antagonists (LTRAs). We assessed whether 
weight status modified the response to low-dose ICS and 
LTRA Step-2 monotherapy.
Methods A historical cohort study from clinical data 
linked to administrative databases was conducted 
among children aged 2–18 years with specialist-
diagnosed asthma who were initiating or continuing a 
Step-2 monotherapy from 2000 to 2007 at the Montreal 
Children’s Hospital Asthma Centre. The outcome was 
time-to-management failure defined as any step-up 
in therapy, acute care visit, hospitalisation or oral 
corticosteroids for asthma, whichever occurred first. 
The independent and joint effects of weight status 
(body mass index [BMI] percentile) and time-varying 
treatment on time-to-management failure were 
estimated with marginal structural Cox models. The 
likelihood ratio test (LRT) and relative excess risk 
due to interaction (RERI) were computed to assess 
treatment effect modification by weight status on the 
multiplicative and additive scales.
results Of the 433 and 85 visits with a low-dose ICS 
and LTRA prescription, respectively, 388 management 
failures occurred over 14 529 visit-weeks of follow-
up. Children using LTRA compared with low-dose 
ICS tended to have an overall higher risk of early 
management failure (HR 1.52; 95% CI 0.72 to 3.22). 
Irrespective of treatment, the hazard of management 
failure increased by 5% (HR 1.05; 95% CI 1.01 to 
1.10) for every 10-unit increase in BMI percentile. An 
additional hazard reduction of 17% (HR 0.83; 95% CI 
0.70 to 0.99) was observed for every 10-unit increase 
in BMI percentile among LTRA users, but not for ICS 
(HR 0.95; 95% CI 0.86 to 1.04). The LRT indicated a 
departure from exact multiplicativity (p<0.0001), and 
the RERIs for ICS and LTRA were −0.05 (95% CI −0.14 
to 0.05) and −0.52 (95% CI −1.76 to 0.71).
conclusions Weight status was associated with 
earlier time-to-management failure in children 
prescribed Step-2 therapy. This hypothesis-generating 
study suggests that LTRA response increases in 
children with higher BMI percentiles, although further 
research is warranted to confirm findings.
IntroductIon
Over the last few decades, the prevalence of 
obesity in paediatric asthma has risen rapidly, 
with an estimated 20% and 30% of children 
with asthma reported to be overweight and 
obese, respectively.1 2 As its own distinct clin-
ical phenotype,3 obese children with asthma 
have been shown to be exacerbation-prone 
and difficult to manage.2 4–6 As a result, these 
vulnerable children are often at a higher risk 
of school absenteeism7 and decreased quality 
of life8 when compared with their normal-
weight counterparts.4 Along with increased 
morbidity, obese patients with asthma may 
have a suboptimal therapeutic response to 
inhaled corticosteroids (ICS),6 9 10 which 
constitute the current gold standard for 
asthma management in children.11
Poor response to ICS among obese 
patients has been hypothesised to be due 
to altered lung function and inflammatory 
processes.4 12–14 The excess weight-induced 
mechanical stress placed on the thoracic 
cage can lead to higher degrees of airflow 
limitation, which some speculate may lead 
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to reduced peripheral lung deposition of inhaled ther-
apies.9 13 There is also support for an alternative inflam-
matory process in obese-asthma that is independent of 
the classical Th2 eosinophilic-mediated pathway,14–16 
with eosinophilic phenotypes known to be corticoste-
roid-responsive in patients with asthma without refrac-
tory disease. As the obese-asthma inflammatory pathway 
may be mediated by a neutrophilic mechanism,17 experts 
have questioned the applicability of the current treat-
ment guidelines to patients with excess weight,18 recom-
mending low-dose ICS as the first-line Step-2 maintenance 
therapy for mild persistent asthma.19 20 Nevertheless, 
findings supporting a differential response attributed to 
weight status in children have yet to be confirmed.
Leukotriene receptor antagonists (LTRAs) are a 
second-line Step-2 oral maintenance monotherapy that 
inhibit both eosinophil-mediated and neutrophil-medi-
ated inflammation and whose action is independent of 
lung mechanics to achieve therapeutic targets; it may 
thus serve as an alternative therapy in patients with 
excess weight.21–23 Given the paucity of studies evaluating 
the comparative effectiveness of LTRA monotherapies 
by weight status in children with asthma, low-dose ICS 
remains the preferred first-line Step-2 therapy across 
guidelines. Thus, the potential benefits of LTRA versus 
ICS in terms of achieving control and preventing exac-
erbation in children with excess weight have not been 
established.
The primary objective of this study was to assess if weight 
status modifies the response to low-dose ICS and LTRA 
monotherapy, specifically by evaluating whether the 
association between Step-2 therapies and time-to-man-
agement failure is modified by body mass index (BMI) 
percentile in children with asthma. We hypothesised that 
weight-related changes to lung physiology and mechanics 
would lead to a differential response to Step-2 therapies 
in children with higher BMI status.
Methods
research design
A historical cohort study was conducted using a database 
that linked clinical chart data to Quebec administrative 
health and drug claims databases for the purposes of eval-
uating the effectiveness of different asthma maintenance 
therapies and risk factors for poor outcomes. The Paedi-
atric Asthma Database contained 15 147 clinical records 
of 4621 children who visited the Asthma Centre of the 
Montreal Children’s Hospital between January 2000 and 
December 2007.
Patient and public involvement
Because this is a database study, the research question and 
outcomes measured were not informed by patients, nor 
were patients involved in the recruitment to or conduct 
of the study. As all data were anonymised, study results 
cannot be directly disseminated to the patients included 
in this study.
data sources
The Paediatric Asthma Database included detailed infor-
mation on sociodemographics, asthma diagnosis, severity 
and control indicators as assessed by the consulting asthma 
specialist, environmental exposures, lung function test 
results and medical chart records of all prescribed asthma 
maintenance and/or rescue treatments, with the indica-
tion for medication use clearly labelled, for each visit at 
the Asthma Centre. Patient records from the Paediatric 
Asthma Database were linked to the hospital admission 
(MED-ECHO), Régie de l’assurancemaladie du Québec 
(RAMQ) medical service and prescription claims admin-
istrative databases. The RAMQ medical service database 
contains information on the type, location of service 
delivery and diagnostic codes using the International 
Classification of Diseases 9th and 10th revisions (ICD-9; 
ICD-10) for all medical services billed by physicians. The 
MED-ECHO database includes admission and discharge 
codes for all hospitalisations in Quebec. Children are 
provided universal access to all healthcare services in 
Quebec. Lastly, the RAMQ prescription claims database 
contains data on all drugs dispensed to patients enrolled 
in the Public Drug Insurance Plan (42% of Quebec resi-
dents).24
study population
Children were included if they were aged 2–18 years, 
consulted the Asthma Centre during the study period 2000–
2007, had an asthma diagnosis confirmed by a specialist, 
and were prescribed low-dose ICS or LTRA (Step-2) main-
tenance monotherapies as documented in the medical 
chart at the index visit date. Patients were excluded if they 
were diagnosed with bronchopulmonary dysplasia or cystic 
fibrosis or were not enrolled in the public drug or health 
insurance plan at least 6 months prior to and 3 months 
following the visit date. The study population included 
children who were initiating or continuing a prescription 
of low-dose ICS or LTRA. Children initiating (‘incident’ 
users) and continuing therapy (‘prevalent’ users) were 
defined as those who had no claims and at least one claim 
for low-dose ICS or LTRA, respectively, in the 6 months 
preceding the index date (‘lookback period’). Children 
who had claims for medium-dose or high-dose ICS or ICS 
in combination with long-acting beta-2 agonists (LABAs) 
or LTRA during the lookback period were excluded. The 
cohort entry (index) date was defined as the date at which 
patients met all inclusion criteria. We included all visit 
dates eligible for cohort entry based on the above criteria; 
thus, some children contributed multiple entry dates (also 
known as ‘trials’25) to the cohort and thus could contribute 
data to both ICS and to LTRA at different points in time. 
Follow-up ended at the outcome date, end of insurance 
coverage, 1-year post index date or 31 December 2007, 
whichever occurred first.
outcome
Management failure was defined as a composite endpoint 
that included any of the following events: (1) a step-up 
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in maintenance therapy, that is, higher dose ICS, ICS/
LABA or ICS/LTRA combination therapy dispensed 
during follow-up; (2) a short course of oral corticoster-
oids; (3) an acute care visit; or (4) a hospital admission 
for an asthma exacerbation (ICD-9 493.X; ICD-10 J45.X). 
We instated a lag of 3 days following cohort entry before 
assessing the outcome to exclude the possibility of pre-ex-
isting exacerbations.
exposures
Weight status: BMI percentile
BMI percentiles were computed using Z-scores with age- 
and sex-specific WHO growth reference values from the 
height and weight measurements documented by trained 
healthcare professionals at the Asthma Centre index 
visit.26
Treatment
A time-varying exposure definition was implemented 
to classify Step-2 maintenance therapy use throughout 
follow-up. Children dispensed low-dose ICS, that is, <200 
μg/day (<250 μg/day if ≥12 years old) of hydrofluoroal-
kane-propelled beclomethasone dipropionate or equiv-
alent measured ex-valve,20 were classified as exposed to 
low-dose ICS monotherapy for the duration of the claim. 
Children dispensed LTRA (montelukast or zafirlukast) 
were classified as exposed to LTRA monotherapy for the 
duration of the claim. If the ICS daily dose documented 
in the claims database was discordant with Asthma 
Centre records, the expected duration of the drug claim 
was adjusted to better reflect the prescribed daily dose 
as documented in the medical charts at the index date. 
If a child held an active prescription claim for a Step-2 
maintenance therapy at the index date, he/she was 
considered exposed from cohort entry until the expected 
completion date of that pre-existing drug claim. Gaps of 
no therapy, that is, the time defined by the absence of 
claims for both low-dose ICS and LTRA, were classified as 
periods of ‘treatment non-compliance’, which served as 
a reference group.
time-fixed and time-varying confounders
Sociodemographic variables (age, sex, ethnicity and 
average family income estimated from census data using 
six-digit postal codes), user type (incident vs prevalent), 
asthma phenotype (persistent vs non-persistent), respira-
tory comorbidities (including atopy, recurrent otitis, 
sinusitis, pneumonia, gastro-oesophageal reflux, obstruc-
tive sleep apnoea, bronchopulmonary aspergillosis, vocal 
cord dysfunction or dysphagia), exposure to cigarette 
smoke and morbidity (number of exacerbations in the 
preceding year) were documented at the index visit 
and defined as time-fixed confounders. Time-varying 
confounders included physicians’ global assessment of 
asthma severity and prebronchodilator percent predicted 
forced expiratory volume in 1 s (FEV1) test values as 
they were updated at each visit to the Asthma Centre. 
In some children, higher dose ICS was prescribed as a 
rescue therapy by the Asthma Centre physician, which 
could have confounded treatment effects. Thus, we also 
controlled for higher dose ICS rescue therapy use, where 
the child was classified as using the rescue therapy from 
the date at which he/she claimed the rescue medica-
tion (as prescribed in medical charts) until the end of 
follow-up, and season to account for viral-induced and 
allergy-induced worsening of asthma symptoms.
statistical analysis
We used multiple imputations to address missing data 
for BMI percentile (1.2%), ethnicity (9.3%), percent 
predicted FEV1 (13.1%), exposure to smoking (22.6%) 
and family income (22.9%) at the index date. We did not 
test differences in baseline characteristics between treat-
ment groups, as recommended by the Strengthening 
the Reporting of Observational Studies in Epidemiology 
guidelines. We fit extended Cox models to obtain condi-
tional associations for Step-2 maintenance therapies and a 
10-unit increase in BMI percentile at baseline with respect 
to the hazard of management failure, while adjusting for 
all measured confounders. We also fit marginal struc-
tural Cox models for time-varying treatments, which have 
the added advantage of correcting for time-dependent 
confounding.27 To correct for possible selection bias 
potentially induced by time-dependent confounding and 
losses to follow-up, we fit two separate propensity score 
models, for treatment use and censoring, respectively, 
at each follow-up week interval, conditional on all meas-
ured confounders and covariates. We then computed 
stabilised inverse probability of treatment and censoring 
weights for each follow-up week interval.27 28 We used the 
product of these weights in the estimation of the final 
marginal HRs for treatment.27 28 In the marginal model, 
the weighted approach enables the estimation of an HR 
that compares the marginal hazards of time-to-manage-
ment failure between treatment categories (non-com-
pliant, low-dose ICS or LTRA) had all patients been 
consistently taking their LTRA monotherapy, their 
low-dose ICS monotherapy or been non-compliant (ie, 
not exposed to any treatment), throughout the follow-up 
period. If the propensity score model is correctly 
specified, the marginal structural model emulates a 
randomised controlled trial contrasting the expected 
time-to-event outcomes of each treatment arm (no 
treatment, low-dose ICS and LTRA monotherapy) had 
all patients remained in their assigned arm throughout 
follow-up—an estimate that reflects what would happen 
in an ideal setting (efficacy).29 30 Conversely, the condi-
tional model estimates an HR comparing the hazards of 
time-to-management failure between patients exposed to 
ICS, LTRA or non-compliance at observed event times 
 T  , given patients’ observed treatment (patterns of use) 
and covariate histories, as well as having remained under 
observation until time T  —an estimate that is reflective of 
real life (effectiveness).
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Figure 1 Study population flow chart. CF, cystic fibrosis; BPD, bonchopulmonary dysplasia; ICS, inhaled corticosteroids; 
LTRA, leukotriene receptor antagonist.
Violations to the proportional hazards assumption were 
investigated by visually inspecting the scaled Schoenfeld 
residuals plot and confirmed with the likelihood ratio 
test (LRT) for improved fit when an interaction term 
with time was included in the model. To obtain condi-
tional and marginal treatment HRs for different weight 
status categories, interaction terms between treatment 
and BMI percentile at baseline was included. When eval-
uating whether treatment effects were modified by BMI 
percentile, we computed the relative excess risk due to 
interaction (RERI)31 and the LRT for the marginal and 
conditional models to assess interaction on the additive 
and multiplicative scales, respectively.
Based on the data distribution, BMI percentiles were 
classified ad hoc into normal (BMI ≤80th percentile) and 
excess weight (BMI >80th percentile) using the median as 
the cut-off point to improve statistical power; this dichoto-
misation was used to estimate joint effects and the specific 
survival curves for each Step-2 therapy and weight cate-
gory combination, as well as the treatment (ICS or LTRA) 
HRs stratified by weight category. Sensitivity analyses 
were conducted to verify (1) potential non-linear rela-
tionships between BMI percentile and treatment effects 
with restricted cubic splines; (2) effects observed only 
in those with persistent asthma; and (3) the robustness 
of methods for handling missing data (multiple imputa-
tions vs complete case analysis). In addition, subgroup 
analyses explored whether findings differed in incident 
and prevalent users. Robust SEs were used to account for 
the inclusion of multiple ‘person-visits’ and the weights 
in the marginal model. Data management was performed 
with SAS V.9.4, and survival curves were illustrated using 
Stata Statistical Software V.13, while other analyses were 
performed using RStudio V.1.0.44.
results
Of the total 15 147 visits (N=4621 patients) in the Paedi-
atric Asthma Database, 518 (n=342) person-trials were 
included in the final cohort (figure 1), of whom 85 and 
433 were prescribed LTRA and low-dose ICS at the index 
visit, respectively. The number of visits contributed by 
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Table 1 Baseline characteristics of incident and prevalent 
users prescribed Step-2 maintenance therapy
Baseline characteristics LTRA (n*=85) ICS (n*=433)
Age, ¯x± σ 11.3 ± 3.9 9.7±4.2
Female, n (%) 42 (49.4) 186 (43.0)
Ethnicity, n (%)
  Caucasian 68 (80.0) 261 (60.3)
  Black 8 (9.4) 64 (14.8)
  Other 9 (10.6) 108 (24.9)
Income, M±IQR 45 684 (19 929) 40 187 (19 527)
Weight status, n (%)
  BMI ≤80th percentile 44 (51.8) 218 (50.4)
  BMI >80th percentile 41 (48.2) 215 (49.6)
Exposure to cigarette smoke, 
n (%)
41 (48.2) 121 (27.9)
% Predicted FEV1, ¯x± σ 99±12.8 98±14.1
Asthma phenotype, n (%)
  Episodic/Seasonal 37 (43.5) 174 (40.2)
  Persistent 48 (56.5) 259 (59.8)
Global assessment of severity, 
n (%)
  Mild 84 (98.8) 340 (78.5)
  Moderate-severe 1 (1.2) 93 (21.5)
Exacerbations for asthma in 
previous year, n (%)
Acute care visits
  0 15 (28.6) 64 (14.78)
  1 18 (20.0) 99 (22.86)
  2 22 (31.4) 104 (24.01)
  ≥3 30 (20.0) 142 (32.8)
Hospitalisations
  0 83 (97.7) 368 (85.0)
  ≥1 2 (2.3) 65 (15.0)
Oral corticosteroids
  0 79 (94.3) 298 (68.8)
  ≥1 6 (5.7) 135 (31.2)
Asthma-related comorbidities, 
n (%)†
  None 55 (64.7) 202 (46.7)
  Atopy‡ 26 (30.6) 214 (49.4)
  Upper/Lower respiratory 
conditions§
7 (8.2) 43 (9.9)
Triggers, n (%)†
  Viral 54 (63.5) 310 (71.6)
  Allergic 38 (44.7) 191 (44.1)
  Effort 53 (62.4) 189 (42.7)
  Temperature 7 (8.2) 66 (14.9)
Continued
each patient is illustrated in online supplemental figure 
e-1.
Children included in the cohort were mostly male 
(56%), aged 5 years and older (87.5%), with a mean treat-
ment period of 11 weeks (ranging from 0 to 52 weeks). 
Children prescribed low-dose ICS had more moder-
ate-severe asthma and comorbidities, as well as higher 
healthcare utilisation in the previous year, than those 
prescribed LTRA. On average, children prescribed LTRA 
were older, had higher family income, and reported 
more exercise-triggered symptoms compared with those 
prescribed low-dose ICS (table 1).
There were a total of 338 management failures during 
the 14 529 trial-weeks of follow-up. The incidence rates 
for management failure remained relatively stable 
between prescribed treatment at the index visit (ICS vs 
LTRA), regardless of the number of visits contributed 
by the child in the analysis; however, the incidence rate 
was elevated for children using LTRA during follow-up 
who contributed two or more visits compared with those 
contributing a unique visit (online supplemental tables 
e-1a and e-1b). In the main effects model, the conditional 
and marginal hazard of management failure increased by 
6% (HR 1.06; 95% CI 1.01 to 1.10) and 5% (HR 1.05; 
95% CI 1.01 to 1.10) for every 10-unit increase in BMI 
percentile, respectively (table 2). While not statistically 
different, results suggested a trend towards an overall 
poorer response to LTRA than to low-dose ICS (condi-
tional HR 1.15, 95% CI 0.68 to 1.61; marginal HR 1.52, 
95% CI 0.72 to 3.22) with respect to time-to-management 
failure.
In the conditional and marginal models that include 
an interaction term between Step-2 therapy and BMI 
percentile, a clinically relevant reduction in the risk of 
management failure was not observed with increasing 
BMI percentile among ICS users. In contrast, for chil-
dren treated with LTRA, an additional 22% (HR 0.78; 
95% CI 0.67 to 0.91) and 17% reduction (HR 0.83; 
95% CI 0.70 to 0.99) in the conditional and marginal 
hazards of management failure were observed for every 
increase of 10 BMI percentile units, respectively. Of note, 
inclusion of the interaction term of treatment by BMI 
percentile significantly improved the fit (LRT p<0.001) 
in both models, indicating the presence of treatment 
effect modification on the multiplicative scale; the RERIs 
suggested a trend towards subadditivity, that is, the joint 
effects of BMI and treatment were less than the sum of 
their individual effects on the additive scale, which was 
most pronounced for LTRA (marginal RERI −0.52; 95% 
CI −1.76 to 0.71) relative to ICS (marginal RERI −0.05; 
95% CI −0.14 to 0.05) (table 2). In the spline sensitivity 
analysis, a non-linear relationship between BMI percen-
tile and the hazard of management failure was visually 
evident for ICS users, but not LTRA users, indicating 
that models assuming a linear relationship with BMI may 
overestimate the beneficial effect of ICS at an elevated 
weight status, suggesting a blunted response to ICS at 
higher BMI percentiles (online supplemental figure e-2).
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Baseline characteristics LTRA (n*=85) ICS (n*=433)
*Number of person-trials.
†Categories are not mutually exclusive.
‡Atopic conditions comprise eczema, allergic rhinitis, conjunctivitis 
and food allergies.
§Chronic upper or lower respiratory tract comorbidities include a 
history of recurrent otitis, sinusitis, pneumonia, gastro-oesophageal 
reflux disease, obstructive sleep apnoea, bronchopulmonary 
aspergillosis, vocal cord dysfunction or dysphagia.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; ICS, 
inhaled corticosteroids; LTRA, leukotriene receptor antagonist.
Table 1 Continued
Table 2 Conditional and marginal model estimates for 
time-to-management failure
Models 
Average HR (95% 
CI)*
Conditional Marginal
Main effects model
BMI percentile (for 
every 10 units)
1.06 (1.01 to 1.10) 1.05 (1.01 to 1.10)
ICS vs treatment 
non-compliance
0.91 (0.69 to 1.20) 0.93 (0.70 to 1.23)
LTRA vs treatment 
non-compliance
1.05 (0.68 to 1.61) 1.11 (0.72 to 1.70)
LTRA vs ICS 1.15 (0.74 to 1.80) 1.52 (0.72 to 3.22)
Model with 
interaction term
BMI percentile (for 
every 10 units)
1.09 (1.03 to 1.16) 1.08 (1.02 to 1.15)
ICS vs treatment 
non-compliance
1.45 (0.66 to 3.16) 1.37 (0.61 to 3.10)
LTRA vs treatment 
non-compliance
7.94 (2.56 to 24.69) 4.62 (1.27 to 16.88)
ICS × BMI percentile 0.94 (0.85 to 1.03) 0.95 (0.86 to 1.04)
LTRA × BMI 
percentile
0.78 (0.67 to 0.91) 0.83 (0.70 to 0.99)
LRT p value† <0.001 <0.001
RERI ICS × BMI 
percentile‡
−0.06 (−0.16 to 0.04) −0.05 (−0.14 to 0.05)
RERI LTRA × BMI 
percentile‡
−1.29 (−3.55 to 0.97) −0.52 (−1.76 to 0.71)
*After accounting for age, sex, ethnicity, income, user type, global 
assessment of severity score, number of exacerbations in previous 
year, exposure to smoke, asthma-related comorbidities, triggers, % 
predicted FEV1, ICS rescue use and season.
†LRT assesses improved goodness of fit when comparing nested 
models (the model with interaction terms vs the main effects model); 
a p value <0.05 indicates a statistically significant improved fit, that 
is, explaining a greater proportion of the variance in the outcome, and 
the likely presence of effect measure modification on the multiplicative 
scale.
‡RERI=HRTherapy×BMI – HRTherapy – HRBMI +1; a negative RERI can be 
interpreted as the hazard reduction due to interaction on the additive 
scale (subadditivity), adjusted for measured confounders.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; ICS, 
inhaled corticosteroids; LRT, likelihood ratio test; LTRA, leukotriene 
receptor antagonist; RERI, relative excess risk due to interaction.
The average conditional and marginal HRs for 
different treatment–weight status categories (≤80th vs 
>80th percentile) were also estimated in relation to a 
common reference group, namely normal-weight chil-
dren who were non-compliant to treatment (table 3). 
Compared with this reference group, the marginal HRs 
of management failure for LTRA were 1.72 (95% CI 1.01 
to 2.93) for normal-weight and 1.14 (95% CI 0.61 to 2.13) 
for excess-weight patients. For normal-weight and excess-
weight children on ICS, the estimates were 0.96 (95% 
CI 0.62 to 1.48) and 1.21 (95% CI 0.84 to 1.74), respec-
tively, suggesting a trend towards a reduced response to 
ICS with higher BMI. Children with excess weight who 
were also non-compliant to treatment had a marginal HR 
of 1.38 (95% CI 1.00 to 1.89). The conditional model 
demonstrated similar trends (table 3).
The HRs for different treatment comparisons strat-
ified by normal weight and overweight subgroups are 
displayed graphically in figure 2. Survival curves for 
treatment and weight status category are illustrated in 
figure 3. Trends and conclusions remained consistent 
in incident and prevalent users, when restricting to 
patients with persistent asthma, and different methods of 
handling missing data (online supplemental tables e-2, 
e-3, and e-4).
dIscussIon
In this cohort of children with asthma treated with Step-2 
therapy, BMI percentile was associated with an overall 
increased risk of management failure. Our findings 
suggest a differential response to Step-2 maintenance 
therapies by weight status for LTRA. Whereas there was 
an overall greater risk of failure in children treated with 
LTRA, this was not observed in children with excess 
weight. No statistically significant interaction with weight 
was observed in children treated with low-dose ICS, 
although there was a trend for reduced response in chil-
dren with higher BMIs.
Obesity is an established risk factor for poor control. 
We observed an overall 5%–6% increased risk of Step-2 
monotherapy treatment failure for every 10-unit increase 
in BMI percentile in the main effects model and up to 
a 40% higher risk of failure in overweight children who 
were non-compliant to treatment in the analysis displaying 
HRs for different treatment–weight status categories. 
This is consistent with a recent meta-analysis of observa-
tional data including 46 070 children, which identified 
obesity as a significant determinant of asthma exacerba-
tions (OR 1.17; 95% CI 1.03 to 1.34).5 Our results also 
suggest a differential response to Step-2 monotherapy 
by weight status. When compared with periods of treat-
ment non-compliance and contrary to our hypothesis, 
no statistically significant treatment effect modification 
by weight was observed with ICS. However, whereas there 
was a trend towards overall poorer response for LTRA 
compared with low-dose ICS in the main effects model, 
a greater response to LTRA was observed at higher BMI 
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Table 3 Conditional and marginal joint effects of treatment and weight status on time-to-management failure
Treatment Weight status Events/Visit-weeks (n) 
Average HR (95% CI)* 
Conditional Marginal
LTRA monotherapy BMI >80th percentile 12/563 1.09 (0.60 to 2.00) 1.14 (0.61 to 2.13)
BMI ≤80th percentile 16/470 1.69 (1.00 to 2.88) 1.72 (1.01 to 2.93)
Overall 28/1033
Low-dose ICS monotherapy BMI >80th percentile 59/2184 1.18 (0.83 to 1.69) 1.21 (0.84 to 1.74)
BMI ≤80th percentile 61/2771 0.92 (0.60 to 1.43) 0.96 (0.62 to 1.48)
Overall 120/4955
Treatment non-compliance BMI >80th percentile 95/3531 1.40 (1.03 to 1.92) 1.38 (1.00 to 1.89)
BMI ≤80th percentile† 96/5010 1.00 (reference) 1.00 (reference)
Overall 191/8541
*After accounting for age, sex, ethnicity, income, user type, global assessment of severity score, number of exacerbations in previous year, exposure 
to smoke, asthma-related comorbidities, triggers, % predicted FEV1, ICS rescue use and season.
†Reference category.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist.
Figure 2 Conditional and marginal treatment HRs (95% CI) stratified by weight category and overall averages. The reference 
groups are treatment non-compliance (all weight categories), treatment non-compliance among those with a BMI ≤80th 
percentile (‘normal weight’) and treatment non-compliance among those with a BMI >80th percentile (‘overweight’). BMI, 
body mass index; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist.
percentiles when weight status was taken into account as a 
potential treatment response modifier in the interaction 
model. In other words, ICS and LTRA monotherapies 
seemed to be equally effective at prolonging time-to-man-
agement failure in children with a BMI >80th percentile, 
while low-dose ICS appeared to be, on average, more 
effective than LTRA in children with a BMI ≤80th percen-
tile as graphically displayed.
To our knowledge, no previous studies have evaluated 
the differential response to LTRA relative to low-dose 
ICS by weight status in children, and the marginal struc-
tural models applied in this study are novel to paediatric 
asthma, although this approach has been previously 
implemented in a few adult asthma studies.32–34 Never-
theless, in a post-hoc analysis of a placebo-controlled 
randomised trial with 1041 children initiating low-dose 
ICS, Forno et al10 reported that lung function and bron-
chodilator response were diminished by 0.4% and 0.25% 
for every 10% increase in BMI percentile, respectively. 
The authors did not evaluate response to LTRA for 
different BMIs. Yet, consistent with our findings, they 
demonstrated that normal-weight children initiating 
ICS experienced a significant reduction in the number 
of emergency department visits or hospitalisations for 
asthma during follow-up, whereas no improvement was 
observed in those with excess weight.35 Post-hoc analyses 
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Figure 3 Marginal probability of not experiencing a 
management failure event, that is, remaining adequately 
controlled, for each weight status–treatment combination. 
BMI, body mass index; ICS, inhaled corticosteroids; LTRA, 
leukotriene receptor antagonist.
of adult randomized controlled trials also reported a 
differential effect of Step-2 therapy across weight status, 
although results were conflicting. Peters-Golden et al36 
noted that the effect of LTRA on asthma control days 
remained constant across weight categories, while that 
of low-dose ICS decreased with increasing BMI. Normal-
weight adult patients randomised to low-dose ICS had a 
significantly greater percentage of asthma control days 
than those randomised to LTRA; however, this difference 
did not persist in patients with excess weight, consistent 
with our findings.36 Similarly, Sutherland et al37 showed 
that patients with excess weight were more likely to expe-
rience a reduced response to ICS monotherapy in relation 
to exhaled nitric oxide levels when compared with their 
normal-weight counterparts, although without increasing 
the risk of exacerbation; in contrast, a reduced response 
to LTRA was not observed among those with higher 
BMI.37 In two other post-hoc analyses of RCTs, low-dose 
ICS was superior to LTRA with respect to improving 
FEV1, symptom scores and short-acting beta-2 agonist use 
across all weight categories, although it was suggested 
that response to both treatments may be attenuated at 
higher BMIs.38 39 Our paediatric study further supports 
ICS as a more effective option than LTRA in normal-
weight children but not in overweight children, which 
aligns with Peters-Golden et al,36 where the response to 
LTRA was observed to increase with higher BMI.
There are several mechanisms underlying a possible 
differential response to LTRA and/or ICS by weight 
status in children. First, obesity has been shown to 
adversely affect pulmonary physiology by changing the 
elastic properties of the chest wall, leading to reduced 
forced vital capacity, FEV1 and peripheral airway diam-
eter.40 In some children, the excess weight placed on the 
thoracic cage may inhibit lung expansion, which could 
lead to reduced absorption and deposition of inhaled 
therapies in the lower airways. Anderson and Lipworth9 
showed that cortisol suppression was reduced in adults 
with asthma who were overweight when compared with 
their normal-weight counterparts, which they attributed 
to possible insufficient absorption and deposition of 
inhaled steroids.9 Perhaps, in children with higher 
weight-related lung compression, LTRA could offer an 
additional benefit over ICS as its efficacy is not affected 
by lung mechanics. Second, obese patients may exhibit 
an inflammatory process that is phenotypically different 
from the traditional Th2-dependent pathway—the latter 
underpins guidelines recommending low-dose ICS as a 
first-line Step-2 maintenance therapy. Moreover, some 
studies have suggested an airway inflammatory process 
partially mediated by leukotrienes, which may explain 
the increased response to LTRA at higher BMI percen-
tiles in our study.16 18 Lastly, there is some evidence of 
shared genetic factors in the phenotypic variation of both 
obesity and asthma, including response to treatment.41 
Polymorphisms in the B2-adrenergic and glucocorticoid 
receptor genes, as well as tumour necrosis factor-α, have 
been linked to asthma, obesity, and in some cases treat-
ment response.42–44 Whatever the mechanism explaining 
the observed greater response to LTRA in those with 
excess weight, the findings suggest considering LTRA 
in patients with asthma with excess weight, if not as first 
line Step-2 therapy, at least as an alternative in those with 
suboptimal response to ICS, prior to step-up therapy.
The strengths of this study include specialist-diag-
nosed asthma (vs self-report), the availability of clearly 
recorded data on Asthma Centre physician prescriptions 
(type, dosage, and intended use of the asthma medica-
tion), as well as updated information on severity indica-
tors throughout the follow-up period, which enabled the 
implementation of the marginal structural Cox model. In 
addition to a more intuitive interpretation, the marginal 
structural model generates a marginal HR that avoids 
biases arising from complicated cases of time-dependent 
confounding and non-collapsibility that are inherent to 
the conditional HR.45 46 Study findings should be inter-
preted in light of several limitations. Despite the inclusion 
of multiple covariates to adjust for differences between 
treatment groups, we suspect residual confounding by 
indication in this retrospective cohort analysis; indeed, 
children using their Step-2 therapies had similar or 
slightly higher HRs of management failure than those 
who were non-compliant to treatment, suggesting that 
the latter may have stopped using prescribed therapy 
because of milder symptoms compared with those who 
continued therapy. This residual confounding was mini-
mised in the prevalent user subgroup results, since these 
children likely had a more persistent phenotype. Yet 
the consistency of findings in relation to the overall and 
treatment-specific effects by weight status on manage-
ment failure in the subgroup analyses, irrespective of 
the marginal or conditional models, and the use of BMI 
as continuous or dichotomous variables, attests to the 
robustness of the results. We could not perform additional 
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subgroup analyses based on age and sex due to our small 
sample sizes; however, we acknowledge the possibility 
that the effect of BMI percentile on time-to-manage-
ment failure may vary across prepubertal, pubertal and 
postpubertal children due to developmental differences 
and hormones affecting adiposity and growth trajectory.4 
Finally, because participants had to be enrolled in the 
Quebec public drug insurance programme, 49% of the 
original cohort were excluded, resulting in a reduced 
sample size and lower statistical power as well as an 
under-representation of children from higher income 
families who were privately insured. Moreover, partici-
pants were recruited from a tertiary care asthma clinic. 
Therefore, our findings may not be generalisable to 
children with asthma covered by private drug insurance, 
of higher socioeconomic status, or those not receiving 
specialised care.
In conclusion, our findings provide clinical insight 
into the association between weight status and treatment 
response in children initiated on Step-2 maintenance 
monotherapy. Children with higher BMI percentiles 
were overall more likely to experience early management 
failure despite Step-2 maintenance therapythan their 
normal-weight counterparts. Of interest, LTRA seems 
to achieve best response at higher BMI percentiles. 
While higher BMI status appears to be associated with a 
trend towards a reduced response to low-dose ICS, this 
association did not reach statistical significance. While 
addressing weight-reduction approaches to overcome 
challenges associated with obese-asthma, consideration 
may be given to LTRAs as an alternative Step-2 mono-
therapy in children with excess weight or at least in those 
with suboptimal response to low-dose ICS. However, 
given the limitations of this retrospective cohort study, 
further research is warranted to determine whether ICS 
and LTRA monotherapies are comparable in terms of 
prolonging time-to-management failure in higher risk 
obese children with asthma.
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